| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | -0.063 | 0.09 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.085 | 0.09 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.09 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.09 |
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | -0.06 | 0.09 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.081 | 0.09 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.058 | 0.09 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.057 | 0.09 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.098 | 0.09 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | 0.087 | 0.09 |